MHAT National Heart Hospital EAD — Clinical Trial Site

32 Registered trials

9 Currently recruiting

Organisation

MHAT National Heart Hospital EAD

Location

Sofiya, Bulgaria

Identifier

ORG-100031035

Address

Ulitsa Konyovitsa 65, 1309, Bulgaria

Departments

#7403: Clinic of Neurology diseases
0906: Department of Noninvasive Cardiology
4001: Clinic of Neurology Diseases
7003: Clinic of Neurology Diseases
Cardiology clinic
Cardiology Clinic, Department of Cardiology
Cardiology Clinic, Department of Invasive Cardiology
Cardiology Department
Clinic in Neurology Diseases
Clinic of cardiology
Clinic of Cardiology, Department of Cardiology
Clinic of Neurological Diseases
Clinic of Neurology
Clinic of neurology diseases
Clinic of Vascular Surgery and Angiology
Department of Cardiology
Department of Child Cardiology at Pediatric Clinic
Department of Dialysis Treatment
Department of Invasive Cardiology
Department of noninvasive cardiology at Clinic of Cardiology
Dept. Pediatric Cardiology
Pediatric Clinic

Clinical trials at this site (32)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults… Recruiting

2024-519830-22-00 Heart failure due to systemic left ventricular systolic 5 2026-04-27
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A study to learn more about how well finerenone works, how safe it is, and how it moves into, through, and out of the body compared to place… Recruiting

2024-519829-38-00 Heart failure due to systemic left ventricular systolic 5 2026-01-09
Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation. Recruiting

2025-521377-14-00 Atrial fibrillation 4 2025-10-06
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
GenePHIT: A study to learn more about how well a new gene therapy (AB-1002) works and its safety in participants with congestive heart failu… Ended

2024-510581-17-00 Adult subjects with New York Heart Association (NYHA) C 4 2024-11-05
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
A Phase 3 study to compare long-term efficacy and safety of macitentan 75 mg versus 10 mg in Pulmonary Arterial Hypertension. Ended

2024-515669-32-00 Pulmonary arterial hypertension 5 2020-06-30
Parent and/or Legal Guardian ICF and Adult patient ICF: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study wi… Ended

2022-501012-34-00 Pulmonary Arterial Hypertension 5 2020-02-27
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertens… Ended

2023-509305-68-00 Pulmonary arterial hypertension (PAH) 5 2019-05-16
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Ch… Ended

2023-510148-19-00 Chronic Heart Failure 4 2024-07-03
A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended

2023-503315-15-00 Thrombolysis of symptomatic proximal vein thrombosis 4 2023-12-20